Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma has confirmed details for its 2025 Annual General Meeting, which will be held in hybrid format at a Melbourne venue and online on 29 January 2026, following an extension of time granted by the corporate regulator. Shareholders will be asked to consider the company’s statutory reports for the year ended 30 June 2025, vote on the re-election of directors, adopt the 2025 remuneration report and approve a long-term incentive grant of performance rights to the CEO and managing director, with the meeting positioned as a key forum for engagement on management, governance and executive pay.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an Australia-based specialty pharmaceutical company focused on developing, manufacturing and marketing branded and generic medicines, with a particular emphasis on complex and hard-to-formulate products for domestic and international markets.
YTD Price Performance: -37.22%
Average Trading Volume: 556,881
Technical Sentiment Signal: Sell
Current Market Cap: A$253.5M
See more data about MYX stock on TipRanks’ Stock Analysis page.